Trials / Completed
CompletedNCT02718937
Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Biota Pharma Europe Limited · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BTA-C585 oral capsule | |
| DRUG | Matching placebo capsules |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2016-03-24
- Last updated
- 2018-05-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02718937. Inclusion in this directory is not an endorsement.